These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 35123069)
1. Decreased Serum Wnt Antagonist Levels in Patients With Active Acromegaly. Chen H; Huang H; Wang Y; Zhang Y; Liu M; Lou Y; Zhang Z; Zhu D; Li P Endocr Pract; 2022 May; 28(5):515-520. PubMed ID: 35123069 [TBL] [Abstract][Full Text] [Related]
2. Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL. Niu CC; Lin SS; Yuan LJ; Chen LH; Yang CY; Chung AN; Lu ML; Tsai TT; Lai PL; Chen WJ BMC Musculoskelet Disord; 2017 Feb; 18(1):61. PubMed ID: 28153008 [TBL] [Abstract][Full Text] [Related]
3. Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling. Wu Y; Xu SY; Liu SY; Xu L; Deng SY; He YB; Xian SC; Liu YH; Ni GX Eur Rev Med Pharmacol Sci; 2017 Feb; 21(3):470-478. PubMed ID: 28239825 [TBL] [Abstract][Full Text] [Related]
4. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover. Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659 [TBL] [Abstract][Full Text] [Related]
5. Increased serum and bone matrix levels of the secreted Wnt antagonist DKK-1 in patients with growth hormone deficiency in response to growth hormone treatment. Ueland T; Olarescu NC; Jørgensen AP; Otterdal K; Aukrust P; Godang K; Lekva T; Bollerslev J J Clin Endocrinol Metab; 2015 Feb; 100(2):736-43. PubMed ID: 25459913 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls. Wanby P; Nobin R; Von SP; Brudin L; Carlsson M J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415 [TBL] [Abstract][Full Text] [Related]
7. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients. Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776 [TBL] [Abstract][Full Text] [Related]
8. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684 [TBL] [Abstract][Full Text] [Related]
9. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318 [TBL] [Abstract][Full Text] [Related]
11. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study. Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108 [TBL] [Abstract][Full Text] [Related]
12. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148 [TBL] [Abstract][Full Text] [Related]
13. Antagonists of Wnt/β-catenin signalling in the periodontitis associated with type 2 diabetes and smoking. Miranda TS; Napimoga MH; Feres M; Marins LM; da Cruz DF; da Silva HDP; Duarte PM J Clin Periodontol; 2018 Mar; 45(3):293-302. PubMed ID: 29243300 [TBL] [Abstract][Full Text] [Related]
14. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Fairfield WP; Sesmilo G; Katznelson L; Pulaski K; Freda PU; Stavrou S; Kleinberg D; Klibanski A Clin Endocrinol (Oxf); 2002 Sep; 57(3):385-90. PubMed ID: 12201832 [TBL] [Abstract][Full Text] [Related]
15. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone. Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306 [TBL] [Abstract][Full Text] [Related]
16. Investigation of the relationship between serum sclerostin and dickkopf-1 protein levels with bone turnover in children and adolescents with type-1 diabetes mellitus. Kurban S; Selver Eklioglu B; Selver MB J Pediatr Endocrinol Metab; 2022 May; 35(5):673-679. PubMed ID: 35411762 [TBL] [Abstract][Full Text] [Related]
17. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients. Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760 [TBL] [Abstract][Full Text] [Related]
18. Acute decline in serum sclerostin in response to PTH infusion in healthy men. Yu EW; Kumbhani R; Siwila-Sackman E; Leder BZ J Clin Endocrinol Metab; 2011 Nov; 96(11):E1848-51. PubMed ID: 21865370 [TBL] [Abstract][Full Text] [Related]
19. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome. Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949 [TBL] [Abstract][Full Text] [Related]